used dihydroartemisinin to intervene in a fibrotic cell model established using a human embryonic lung fibroblast cell line and found that dihydroartemisinin inhibited cell viability, decreased Fe 2+ levels, and inhibited the expression of ferritin heavy chain 1 (FTH1) and nuclear receptor coactivator 4 (NCOA4) genes and proteins
10.3109/1547691X.2013.860644 132 MillerL
Payment and security What payment methods does the vendor accept
There you will find the most detailed and full information regarding lab tests
As innovators change their product lifecycle management approach towards increased patient centricity, transitioning from intravenous (IV) infusion to SC administration with an injection device can be a huge game-changer (patient focus, compliance, differentiation from competitors), with notable examples being Herceptin (trastuzumab, Roche/Genentech), MabThera (rituximab, Roche/Genentech), Actemra (tocilizumab, Roche/Genentech), Benlysta (belimumab, GSK), Entyvio (vedolizumab, Takeda) and others